Cantor Fitzgerald Estimates PACB FY2025 Earnings

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Pacific Biosciences of California in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechnology company will earn ($0.62) per share for the year. The consensus estimate for Pacific Biosciences of California’s current full-year earnings is ($0.91) per share.

PACB has been the subject of a number of other reports. StockNews.com upgraded Pacific Biosciences of California to a “sell” rating in a research report on Thursday, January 9th. Piper Sandler increased their price objective on shares of Pacific Biosciences of California from $2.00 to $2.50 and gave the company a “neutral” rating in a research report on Monday, November 11th. UBS Group downgraded shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Monday, November 11th. Scotiabank lowered their price target on shares of Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating for the company in a report on Monday, November 11th. Finally, The Goldman Sachs Group reduced their price objective on Pacific Biosciences of California from $2.25 to $1.75 and set a “neutral” rating on the stock in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $2.89.

Pacific Biosciences of California Price Performance

Shares of Pacific Biosciences of California stock opened at $1.65 on Wednesday. The firm has a market cap of $451.87 million, a PE ratio of -1.13 and a beta of 1.95. The stock has a 50 day moving average of $1.89 and a 200 day moving average of $1.82. The company has a current ratio of 9.74, a quick ratio of 8.64 and a debt-to-equity ratio of 1.97. Pacific Biosciences of California has a 12 month low of $1.16 and a 12 month high of $7.50.

Institutional Trading of Pacific Biosciences of California

A number of large investors have recently modified their holdings of PACB. Marshall Wace LLP raised its position in Pacific Biosciences of California by 226.6% during the 2nd quarter. Marshall Wace LLP now owns 1,611,300 shares of the biotechnology company’s stock valued at $2,207,000 after purchasing an additional 1,117,966 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Pacific Biosciences of California in the second quarter valued at about $719,000. Federated Hermes Inc. purchased a new stake in Pacific Biosciences of California in the second quarter worth about $612,000. Soros Fund Management LLC grew its holdings in Pacific Biosciences of California by 23.6% during the 3rd quarter. Soros Fund Management LLC now owns 2,098,000 shares of the biotechnology company’s stock worth $3,567,000 after acquiring an additional 400,000 shares in the last quarter. Finally, FMR LLC increased its position in Pacific Biosciences of California by 641.3% during the 3rd quarter. FMR LLC now owns 408,151 shares of the biotechnology company’s stock valued at $694,000 after purchasing an additional 353,092 shares during the period.

Insiders Place Their Bets

In other Pacific Biosciences of California news, insider Oene Mark Van sold 34,405 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $2.03, for a total value of $69,842.15. Following the transaction, the insider now directly owns 1,597,454 shares in the company, valued at $3,242,831.62. This represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.